Therapeutic Duplication Proves Refractory Condition: A Clinical Pearl for PI Attorneys

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

When a plaintiff is prescribed two or more drugs from the same therapeutic class simultaneously, this therapeutic duplication is clinical evidence that their condition is refractory -- resistant to standard single-agent treatment. Learn how to identify and present this pattern as proof of injury severity.

Therapeutic duplication -- the concurrent prescribing of two or more medications from the same pharmacological class -- is a clinical hallmark of a refractory condition, one that does not respond adequately to standard single-drug therapy. When a personal injury plaintiff's pharmacy record shows two NSAIDs, two muscle relaxants, or two neuropathic agents prescribed simultaneously, this is not a prescribing error. It is documented evidence that the plaintiff's condition is severe enough to require multi-agent therapy within a single drug class, and it belongs in every demand package.

• Therapeutic duplication occurs when a prescriber intentionally adds a second agent from the same drug class because the first agent alone is insufficient
• This pattern is clinical shorthand for a refractory condition -- one that resists standard treatment and requires more aggressive pharmacological intervention
• LienScripts tracks every concurrent medication and generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that identifies and explains therapeutic duplication in each case
• Pharmacy fill records objectively document both medications dispensed on overlapping schedules, proving the duplication is intentional and ongoing
• Defense counsel cannot credibly dismiss a condition as minor when the prescriber has been forced to deploy two drugs from the same class to manage it

What Therapeutic Duplication Looks Like

In standard prescribing, a patient receives one medication from each therapeutic class needed. One NSAID for inflammation. One muscle relaxant for spasm. One neuropathic agent for nerve pain. Therapeutic duplication departs from this standard when the single agent proves inadequate.

Common examples in personal injury cases:

Dual NSAIDs: A plaintiff taking both oral meloxicam daily for baseline inflammation and topical diclofenac gel for localized flare-ups. The prescriber has determined that a single NSAID cannot manage both the systemic and localized inflammatory components.

Dual muscle relaxants: A plaintiff taking cyclobenzaprine at bedtime for nighttime spasm relief and methocarbamol during the day for daytime spasm management. The prescriber is using two different agents because neither alone controls spasm throughout the 24-hour cycle.

Dual neuropathic agents: A plaintiff taking gabapentin and duloxetine concurrently. These medications work through different mechanisms -- gabapentin modulates calcium channels while duloxetine inhibits serotonin and norepinephrine reuptake. The prescriber has combined them because neither agent alone provides adequate neuropathic pain relief.

Dual pain strategies: A plaintiff on both a long-acting opioid for baseline pain and a short-acting opioid for breakthrough pain. This combination indicates that baseline pain requires continuous management while episodes of severe breakthrough pain exceed what the long-acting agent can cover.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Therapeutic duplication is something I specifically look for when reviewing a case. In pharmacy practice, we are trained to flag duplications as potential errors. But in the personal injury context, intentional therapeutic duplication tells me the prescriber has exhausted single-agent options and is now layering medications from the same class to achieve adequate symptom control. That is the clinical definition of a refractory condition."

Why Refractory Conditions Matter for Damages

Severity Evidence

A refractory condition is, by definition, more severe than a condition that responds to standard single-agent therapy. When the pharmacy record shows therapeutic duplication, the plaintiff's attorney has objective, prescriber-documented evidence that the condition is not routine, not mild, and not self-limiting. It is severe enough to require the prescriber to deviate from standard single-agent prescribing.

Treatment Complexity

Therapeutic duplication increases treatment complexity. Two medications from the same class means double the side effect exposure within that class, increased drug interaction monitoring, more complex dosing schedules, and more frequent follow-up visits. This treatment complexity is itself a damages element that increases the burden the plaintiff bears because of the defendant's negligence.

Prognosis Implications

Conditions that require therapeutic duplication are less likely to resolve. If a single medication could not control the condition, the prognosis for complete resolution is poorer than for a condition that responded to first-line monotherapy. This has direct implications for future medication cost projections and the duration of damages.

Identifying Therapeutic Duplication in Pharmacy Records

LienScripts pharmacy records make therapeutic duplication easy to identify. Look for:

1. Two medications from the same drug class with overlapping fill dates. If gabapentin was last filled on March 1 for a 30-day supply, and duloxetine was filled on March 5 for a 30-day supply, both are active concurrently. This is intentional therapeutic duplication within the neuropathic pain class.

2. Medications with the same indication but different mechanisms. A plaintiff on both a COX-2 selective NSAID and a non-selective NSAID, or on both gabapentin (calcium channel modulator) and amitriptyline (tricyclic antidepressant used for neuropathic pain), is receiving dual-mechanism therapy for the same condition.

3. Medications from the same class but different formulations. Oral diclofenac and topical diclofenac are both NSAIDs, but the oral form provides systemic anti-inflammatory coverage while the topical form targets a specific area. Concurrent use indicates that neither systemic nor localized therapy alone is adequate.

4. Long-acting plus short-acting combinations. A long-acting medication for baseline management combined with a short-acting version of the same class for breakthrough episodes (for example, extended-release and immediate-release formulations of the same drug) documents a condition that varies in intensity and requires layered pharmacological coverage.

Presenting Therapeutic Duplication in Demand Packages

Structure the argument as follows:

Step 1: Identify the duplication. State that the plaintiff is concurrently taking [Drug A] and [Drug B], both from the [drug class] class, as documented by pharmacy fill records showing overlapping dispense dates.

Step 2: Explain the clinical significance. Standard prescribing uses one agent per class. The prescriber's decision to add a second agent within the same class indicates that single-agent therapy was insufficient -- the condition is refractory to standard treatment.

Step 3: Connect to severity. A refractory condition is more severe, more complex, and more resistant to treatment than a condition that responds to first-line monotherapy. This clinical reality supports higher general damages.

Step 4: Reference the MERIT report. The MERIT report from LienScripts documents each instance of therapeutic duplication with clinical explanation, providing pharmacist-signed evidence that the duplication is clinically meaningful, not accidental.

Countering Defense Arguments

"The prescriber made a mistake -- this is a duplicate prescription."

Intentional therapeutic duplication is distinguishable from prescribing error because the two medications are continued over multiple refill cycles, they may use different dosing schedules, and the prescriber has authorized refills for both concurrently at follow-up visits. A true error would be caught at the first refill authorization.

"Two medications is excessive -- the plaintiff is overmedicated."

The prescriber, not the plaintiff, decides the medication regimen. Two medications from the same class reflects a clinical judgment that the condition requires dual-agent therapy. Characterizing prescriber decisions as "excessive" amounts to the defense practicing medicine without a license.

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages that identifies therapeutic duplication patterns and explains their clinical significance in the context of the plaintiff's injury.

Related Resources

• Co-Prescribed Medications Prove Injury Severity -- Using concurrent prescriptions across classes as severity evidence
• Polypharmacy Burden as a Damages Element -- Quantifying the multi-drug management load
• What Is a MERIT Report? -- Understanding the pharmacist-authored clinical summary